Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder

Sharon Ratner, Nathaniel Laor, Yifat Bronstein, Abraham Weizman, Paz Toren*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Fingerprint

Dive into the research topics of 'Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience

Psychology